Northfield Laboratories Submits Biologics License Application to FDA For Approval of Its Blood Substitute, PolyHeme(TM)

    EVANSTON, Ill. Aug. 28 /PRNewswire/ -- Northfield Laboratories Inc.
 (Nasdaq:   NFLD), a leading developer of an oxygen-carrying blood substitute,
 today reported that it has submitted a Biologics License Application (BLA) to
 the Food and Drug Administration (FDA) seeking approval to market its patented
 blood substitute product, PolyHeme, as an ideal oxygen-carrying resuscitative
 fluid for use in the treatment of urgent, life-threatening blood loss.
     "The submission of the BLA for PolyHeme is a significant milestone for
 Northfield, and marks a first for a blood substitute for human use in the
 U.S.," said Richard DeWoskin, chairman and chief executive officer.  "PolyHeme
 provides a remarkable clinical benefit, and represents more than 16 years of
 product development, clinical studies and data analysis.  More importantly, it
 addresses a large market opportunity and fills an important clinical need.
     "We plan to continue working with the FDA to support the strength of our
 application and to provide any additional information that may be necessary to
 achieve a favorable determination," said DeWoskin.
     Dr. Steven A. Gould, president, said, "The data from our clinical trials
 demonstrate that PolyHeme will support life in seriously injured, bleeding
 patients in the virtual absence of circulating red blood cells, and thereby
 improve survival in situations when blood cannot be used.  We believe these
 results demonstrate the ability of PolyHeme to effectively and safely
 transport oxygen.  This extraordinary survival benefit indicates that PolyHeme
 is capable of addressing a critical, unmet medical need, and has led us to
 file for priority review and fast-track status with the FDA, which we hope
 will lead to accelerated approval of PolyHeme."
     PolyHeme is the only blood substitute that has been safely infused rapidly
 and at large enough dosages to be considered a substitute for acute blood loss
 in trauma and surgical settings.  As a result of the process used to
 manufacture this product, essentially a solution of polymerized hemoglobin,
 PolyHeme has a longer shelf life than blood, requires no cross matching and
 does not transmit disease.
     The current market for blood in the United States is estimated to be in
 the multiple billions of dollars.  There were 12.4 million units of blood
 transfused into approximately 4 million recipients in 1999, according to the
 latest figures available from the National Blood Data Resource Center.  Of
 that amount, about 2.5 million units are used in urgent, acute blood loss
 situations -- Northfield's primary focus.
 
     Annual Business Update
     The company will provide more detail on its regulatory progress in its
 annual business update on August 31, 2001.  This presentation will be webcast
 after the close of the market, at 4:30 p.m. central time, that day.  Anyone
 interested in accessing the presentation should log on to
 http://www.northfieldlabs.com or http://www.videonewswire.com , or, for those
 without Internet access, you may dial in to 888-413-4411 to listen to the
 call.  A replay of the webcast will be available for 30 days after the
 presentation.  The telephonic replay will be available for seven days by
 dialing 888-266-2086 and providing the passcode, 5458560.
     Northfield's annual meeting will take place earlier that day at 2:00 p.m.
 central time to vote on business matters as outlined in its August 3rd proxy
 statement.  Only questions related to those business matters will be taken at
 the meeting.  The business update will not be webcast at corporate
 headquarters.
 
     About the Company
     Northfield Laboratories was founded in 1985.  The company is headquartered
 in Evanston, Illinois, and its stock is traded on the Nasdaq National Market
 System under the symbol NFLD.
 
     Statements in this release that are not strictly historical are "forward-
 looking" statements that are made pursuant to the safe harbor provisions of
 the Private Securities Litigation Reform Act of 1995.  Forward-looking
 statements involve known and unknown risks, which may cause the company's
 actual results in the future to differ materially from expected results.
 Northfield cautions that the FDA approval process for PolyHeme continues to be
 subject to significant risks and uncertainties.  The FDA could refuse to
 accept Northfield's BLA in its current form.  If Northfield's BLA is accepted,
 the FDA could deny its approval for the commercial sale of PolyHeme or could
 require additional clinical tests as a condition to its approval.  If FDA
 approval for the commercial sale of PolyHeme is granted, the indication uses
 for which PolyHeme may be marketed could be significantly limited by the FDA.
 Other risks may include:  competition from other blood substitute products;
 the company's ability to obtain regulatory approval to market PolyHeme
 commercially; the company's and/or its representative's ability to
 successfully market and sell PolyHeme; the company's ability to manufacture
 PolyHeme in sufficient quantities; the company's ability to obtain an adequate
 supply of raw materials; the company's ability to maintain intellectual
 property protection for its proprietary product and to defend its existing
 intellectual property rights from challenges by third parties; the
 availability of capital to finance planned growth; and the extent to which the
 hospitals and physicians using PolyHeme are able to obtain third-party
 reimbursement, as described in the company's filing with the Securities and
 Exchange Commission.
     Visit the Northfield website at:  http://www.northfieldlabs.com .
 
                     MAKE YOUR OPINION COUNT -  Click Here
                http://tbutton.prnewswire.com/prn/11690X58114956
 
 

SOURCE  Northfield Laboratories Inc.